Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth

Oncogene

Volumn 26, Issue 46, 2007, Pages 6619-6629

  Migliaccio, A ^a   Varricchio, L ^a   De Falco, A ^a   Castoria, G ^a   Arra, C ^b   Yamaguchi, H ^c   Ciociola, A ^a   Lombardi, M ^a   Di Stasio, R ^a   Barbieri, A ^b   Baldi, A ^a   Barone, M V ^a   Appella, E ^c   Auricchio, F ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Androgen receptor; Estrogen receptor; Receptor antagonist; Src; Xenografts

Indexed keywords

ANDROGEN RECEPTOR; CYCLIN D1; DNA; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN SH3; PROTEIN TYROSINE KINASE;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL STRAIN 3T3; CELL STRAIN MCF 7; CONTROLLED STUDY; CULTURE MEDIUM; DNA SYNTHESIS; EMBRYO; FIBROBLAST; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN; TUMOR GROWTH; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; HUMANS; MALE; MICE; PEPTIDES; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RECEPTORS, ANDROGEN; RECEPTORS, ESTRADIOL; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; TUMOR CELLS, CULTURED;

MUS MUSCULUS;

EID: 34648849274     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210487     Document Type: Article

References (30)

1. Bonaccorsi L, Carloni V, Muratori M, Salvatori A, Giannini A, Carini M et al. (2006). Androgen receptor expression in prostate carcinoma cells suppresses α6β4 integrin-mediated invasive phenotype. Endocrinology 141: 3172-3182.
2. Castoria G, Barone MV, Di Domenico M, Bilancio A, Ametrano D, Migliaccio A et al. (1999). Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. EMBO J 18: 2500-2510.
3. Castoria G, Lombardi M, Barone MV, Bilancio A, Di Domenico M, Bottero D et al. (2003). Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action. J Cell Biol 161: 547-556.
4. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M et al. (2001). PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J 20: 6050-6059.
5. Castoria G, Migliaccio A, Di Domenico M, Lombardi M, de Falco A, Varricchio L et al. (2004). Role of atypical protein kinase C in estradiol-triggered G1/S progression of MCF-7 cells. Mol Cell Biol 24: 7643-7653.
6. Castoria G, Migliaccio A, Nola E, Auricchio F. (1988). In vitro interaction of estradiol receptor with Ca2+-calmodulin. Mol Endocrinol 2: 167-174.
7. Cato AC, Nestl A, Mink S. (2002). Rapid actions of steroid receptors in cellular signaling pathways. Sci STKE 138: RE9.
8. Chang CS, Kokontis J, Liao ST. (1988). Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240: 324-326.
9. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. (2004). Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39.
10. Coussens LM, Werb Z. (2002). Inflammation and cancer. Nature 420: 860-867.
11. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A et al. (1994). Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478.
12. Cunha GR, Hayward SW, Wang YZ. (2002). Role of stroma in carcinogenesis of the prostate. Differentiation 70: 473-485.
13. Gururaj AE, Rayala SK, Vadlamudi RK, Kumar R. (2006). Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. Clin Cancer Res 12: 1001s-1007s.
14. Kay BK, Williamson MP, Sudol M. (2000). The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J 14: 231-241.
15. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L et al. (2001). Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104: 719-730.
16. Levin ER. (2003). Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 17: 309-317.
17. Lopez-Otin C, Diamandis EP. (1998). Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocrinol Rev 19: 365-369.
18. Marquez DC, Lee J, Lin T, Pietras RJ. (2001). Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor. Endocrine 16: 73-81.
19. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M et al. (2000). Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 19: 5406-5417.
20. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E et al. (1996). Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15: 1292-1300.
21. Migliaccio A, Di Domenico M, Castoria G, Nanayakkara M, Lombardi M, de Falco A et al. (2005). Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action. Cancer Res 65: 10585-10593.
22. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M et al. (1998). Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 17:2008-2018.
23. Pandini G, Mineo R, Frasca F, Roberts Jr CT, Marcelli M, Vigneri R et al. (2005). Androgens up-regulate the insulinlike growth factor I receptor in prostate cancer cells. Cancer Res 65: 1849-1857.
24. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. (2000). Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407: 538-541.
25. Singer CA, Figueroa-Masot XA, Batchelor RH, Dorsa DM. (1999). The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J Neurosci 19: 2455-2463.
26. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R et al. (2002). Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 16: 116-127.
27. Vadlamudi RK, Manavathi B, Balasenthil S, Nair SS, Yang Z, Sahin AA et al. (2005). Functional implications of altered subcellular localization of PELP1 in breast cancer cells. Cancer Res 65: 7724-7732.
28. Verrijdt G, Schoenmakers E, Haelens A, Peeters B, Verhoeven G, Rombauts W et al. (2000). Change of specificity mutations in androgen-selective enhancers. Evidence for a role of differential DNA binding by the androgen receptor. J Biol Chem 275: 12298-12305.
29. Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ. (2002). Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci USA 99: 14783-14788.
30. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM et al. (2000). Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6: 703-706.